https://european-biotechnology.com/wp-content/uploads/2024/04/ICU-banner-666x300.jpg300666Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-13 07:47:382019-09-13 07:47:38Inotrem SA raises €39m to provide POC for nangibotide
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-09-12_um_07.02.33.png663990Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-12 06:22:182019-09-12 06:22:18Ermium Therapeutics bags €6.3m in Series A round
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-09-11_um_08.31.36.png519881Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-11 07:44:522019-09-11 07:44:52Pharvaris BV raises $66m to advance oral HAE drug
London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
PDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.
Antibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
https://european-biotechnology.com/wp-content/uploads/2024/04/ADCT_NOD.png7571352Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-08 14:58:502019-09-08 14:58:50ADC Therapeutics set to go public
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-09-06_um_08.05.08.png5641004Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-06 07:34:152019-09-06 07:34:15iStar Medical SA raises €40.1m
PFF Group NV acquires stake in Autolus Therapeutics
Latest NewsPrague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
Elcin Barker Ergun becomes Menarini CEO
AppointmentsThe Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.
Researchers identify CTLA-4 response marker
Latest NewsGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises €39m to provide POC for nangibotide
Latest NewsFrench biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags €6.3m in Series A round
Latest NewsParis-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
Latest NewsLeiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
4BIO Ventures launches US$50m fund
Latest NewsLondon and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
PDC*line Pharma welcomes Dr Channa Debruyne
AppointmentsPDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.
ADC Therapeutics set to go public
Latest NewsAntibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
iStar Medical SA raises €40.1m
Latest NewsGlucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.